major
challeng
broader
clinic
applic
jack
jumper
ant
venom
immunotherapi
jja
vit
scarciti
ant
venom
need
manual
harvest
wild
ant
adjuv
commonli
use
antigen
spare
vaccin
therebi
could
potenti
major
benefit
extend
jja
suppli
similarli
enhanc
jja
vit
immunogen
purpos
studi
evalu
physicochem
microbiolog
stabil
murin
immunogen
lowdos
jja
vit
formul
novel
polysaccharid
adjuv
refer
delta
inulin
advax
tm
jack
jumper
ant
venom
jjav
protein
stabil
assess
uplcuv
sdspage
sdspage
immunoblot
elisa
inhibit
diffract
light
scatter
use
assess
particl
size
distribut
advax
ph
benzyl
alcohol
quantif
uplcuv
use
assess
physicochem
stabil
jjav
diluent
endotoxin
content
preserv
efficaci
test
use
investig
microbiolog
properti
adjuv
vit
formul
assess
effect
adjuv
jja
venom
immunogen
mice
immunis
four
time
jjav
alon
formul
advax
adjuv
jja
vit
formul
advax
found
physicochem
microbiolog
stabl
least
day
store
c
trend
increas
allergen
potenc
observ
beyond
day
storag
lowdos
jjav
formul
advax
adjuv
induc
significantli
higher
jjavspecif
igg
higher
dose
jjav
alon
consist
power
allergenspar
effect
pharmaceut
data
provid
import
guidanc
formul
storag
use
jja
vit
formul
advax
adjuv
murin
immunogen
studi
provid
strong
rational
plan
clinic
trial
test
abil
advax
adjuv
achiev
jjav
dose
spare
jjaallerg
human
patient
major
challeng
broader
clinic
applic
jack
jumper
ant
venom
immunotherapi
jja
vit
scarciti
ant
venom
need
manual
harvest
wild
ant
adjuv
commonli
use
antigen
spare
vaccin
therebi
could
potenti
major
benefit
extend
jja
suppli
similarli
enhanc
jja
vit
immunogen
purpos
studi
evalu
physicochem
microbiolog
stabil
murin
immunogen
lowdos
jja
vit
formul
novel
polysaccharid
adjuv
refer
delta
inulin
advax
tm
jack
jumper
ant
venom
jjav
protein
stabil
assess
uplcuv
sdspage
sdspage
immunoblot
elisa
inhibit
diffract
light
scatter
use
assess
particl
size
distribut
advax
ph
benzyl
alcohol
quantif
uplcuv
use
assess
physicochem
stabil
jjav
diluent
endotoxin
content
preserv
efficaci
test
use
investig
microbiolog
properti
adjuv
vit
formul
assess
effect
adjuv
jja
venom
immunogen
mice
immunis
four
time
jjav
alon
formul
advax
adjuv
jja
vit
formul
advax
found
physicochem
microbiolog
stabl
least
day
store
c
trend
increas
allergen
potenc
observ
beyond
day
storag
lowdos
jjav
formul
advax
adjuv
induc
significantli
higher
jjavspecif
igg
higher
dose
jjav
alon
consist
power
allergenspar
effect
pharmaceut
data
provid
import
guidanc
formul
storag
use
jja
vit
formul
advax
adjuv
murin
immunogen
studi
provid
strong
rational
plan
clinic
trial
test
abil
advax
adjuv
achiev
jjav
dose
spare
jjaallerg
human
patient
elsevi
bv
right
reserv
rapid
onset
system
allerg
reaction
jack
jumper
ant
myrmecia
pilosula
jja
sting
repres
signific
public
health
problem
southeastern
southwestern
part
australia
affect
popul
immunotherapi
prevent
sting
insect
anaphylaxi
involv
administr
http
elsevi
bv
right
reserv
increas
dose
purifi
insect
venom
induc
clinic
toler
reflect
progress
reduct
venomspecif
ige
increas
jja
venom
immunotherapi
vit
involv
larg
mainten
dose
g
venom
shown
highli
effect
prevent
jja
sting
anaphylaxi
reduc
risk
sever
system
sting
reaction
realworld
experi
show
efficaci
compar
yellow
jacket
better
honeybe
vit
applic
jja
vit
wider
popul
howev
limit
highli
restrict
jja
venom
jjav
extract
avail
product
cost
high
incid
advers
event
adjuv
could
facilit
desir
immun
respons
jjav
allow
allergen
dose
reduct
would
potenti
minimis
advers
effect
reduc
cost
reduc
venom
requir
potenti
candid
adjuv
vit
delta
inulinbas
adjuv
advax
tm
advax
base
plant
deriv
fructan
inulin
poli
fructofuranosyl
inulin
immunolog
activ
solubl
form
formul
delta
inulin
microparticl
size
potent
immuneadjuv
activ
advax
shown
preclin
studi
enhanc
immunogen
broad
rang
vaccin
includ
influenza
hepat
b
viru
hbv
japanes
enceph
sar
coronaviru
hiv
listeria
rsv
anthrax
safeti
efficaci
advax
shown
adult
human
formul
hbv
influenza
vaccin
combin
honeybe
vit
administ
individu
honeybeest
anaphylaxi
advax
shown
safe
well
toler
enhanc
immunogen
honeybe
venom
strongli
enhanc
venomspecif
respons
potenti
marker
success
immunotherapi
understand
stabil
jja
vit
aggreg
potenti
advax
microparticl
combin
formul
essenti
aggreg
decomposit
allergen
compon
jjav
may
affect
allergen
potenc
found
increas
storag
previou
studi
object
current
studi
therefor
explor
stabil
aggreg
potenti
jja
vit
advax
combin
formul
prelud
clinic
trial
lowdos
jja
vit
advax
although
current
anim
model
jjav
allergi
necessari
demonstr
use
murin
immunogen
model
coadministr
jja
vit
advax
safe
well
toler
inclus
advax
adjuv
abl
enhanc
immunogen
lowdos
jjav
chemic
reagent
consum
use
experi
previous
describ
chemic
use
formul
jja
vit
product
pharmacopoei
grade
sucros
polysorb
avantor
centr
valley
pa
usa
benzyl
alcohol
pcca
houston
tx
usa
sodium
chlorid
solut
astrazeneca
north
ryde
nsw
australia
sodium
dihydrogen
phosphat
solut
phebra
lane
cove
west
nsw
australia
disodium
hydrogen
phosphat
safc
st
loui
mo
usa
sodium
chlorid
pfizer
west
ryde
nsw
australia
water
inject
pfizer
baxter
old
toongabbi
nsw
australia
microbiolog
media
atcc
strain
microorgan
oxoid
basingstok
hampshir
uk
pool
posit
sera
pp
high
jjavspecif
posit
ige
level
obtain
jjav
allerg
individu
clinic
proven
histori
allergi
previous
describ
jjav
activ
pharmaceut
ingredi
api
prepar
previous
describ
formul
sucros
solut
produc
clinic
grade
jja
vit
contain
mgml
venom
protein
jjav
diluent
solut
contain
sodium
chlorid
phosphat
buffer
ph
mm
polysorb
benzyl
alcohol
manufactur
pharmaci
depart
royal
hobart
hospit
previous
describ
advax
adjuv
buffer
salin
ph
suppli
vaxin
pti
ltd
bedford
park
adelaid
australia
advax
adjuv
prepar
accord
current
good
manufactur
practic
suppli
steril
suspens
contain
mgml
delta
inulin
microparticl
advaxfre
sampl
jjav
dilut
gml
use
jjav
diluent
advax
includ
formul
jja
vit
advax
first
dilut
use
jjav
diluent
gml
mgml
respect
two
dilut
compon
mix
equal
quantiti
gave
final
concentr
gml
mgml
respect
plan
dose
use
futur
human
trial
allergen
potenc
studi
jjav
dilut
use
jjav
diluent
advax
obtain
final
concentr
gml
venom
mgml
advax
sampl
prepar
use
asept
techniqu
packag
insulin
syring
terumo
elkton
maryland
usa
protect
light
store
c
c
day
baselin
sampl
process
within
min
post
prepar
stabil
sampl
collect
process
h
gml
sampl
also
collect
day
post
storag
except
particl
size
analysi
sampl
analys
without
antigen
extract
jjav
extract
stabil
sampl
centrifug
sampl
transfer
protein
lobind
microtub
eppendorf
ag
hamburg
germani
centrifug
min
rpm
g
c
eppendorf
microcentrifug
pellet
advax
particl
supernat
transfer
fresh
microtub
store
c
analysi
allergen
potenc
gml
sampl
analys
use
jjav
igespecif
elisa
inhibit
assay
previous
describ
briefli
amino
immobil
plate
nunc
roskild
denmark
coat
overnight
c
l
gml
jjav
sodium
carbon
ph
inhibit
mixtur
prepar
ad
ng
jjav
l
pp
dilut
l
phosphat
buffer
salin
ph
contain
polysorb
pbst
bovin
serum
albumin
bsa
jjav
inhibit
mixtur
either
baselin
stabil
sampl
describ
section
posit
control
prepar
dilut
pp
vv
pbst
bsa
neg
control
consist
pbst
bsa
incub
overnight
c
subsequ
venom
coat
solut
discard
plate
wash
three
time
pbst
venomco
plate
incub
l
inhibit
mixtur
posit
control
neg
control
min
room
temperatur
rt
plate
wash
three
time
pbst
l
biotinyl
mous
monoclon
antihuman
ige
antibodi
vv
dilut
pbst
clone
life
technolog
carlsbad
ca
usa
ad
well
incub
dark
min
rt
plate
wash
three
time
pbst
l
streptavidinhorseradish
peroxidas
vv
dilut
pbst
bd
pharmingen
san
diego
ca
usa
ad
well
plate
incub
dark
min
rt
plate
wash
three
time
pbst
l
ultra
tmbelisa
thermo
fisher
scientif
rockford
il
usa
ad
well
plate
incub
dark
min
rt
colour
develop
stop
ad
l
sulphur
acid
absorb
read
nm
util
elisa
plate
reader
spectramax
molecular
devic
sunnyval
ca
usa
sampl
run
triplic
mean
standard
deviat
calcul
percentag
inhibit
sampl
calcul
use
follow
equat
allergen
potenc
jjav
measur
amount
venom
solut
requir
inhibit
ige
bind
jjav
coat
onto
plate
stabil
venom
sampl
calcul
percentag
rel
baselin
sampl
gml
sampl
concentr
mgml
use
centrifug
filter
devic
amicon
kda
nomin
molecular
weight
limit
merck
millipor
darmstadt
germani
mix
sd
sampl
buffer
analys
sdspage
sdspage
immunoblot
assay
previous
describ
pp
use
sdspage
immunoblot
assay
assess
myr
p
allergen
peptid
chang
gml
venom
sampl
analys
uplcuv
use
acquiti
hseri
uplc
water
corpor
milford
massachusett
usa
coupl
acquiti
photo
diod
array
pda
detector
acquiti
uplc
beh
column
x
mm
x
particl
held
c
use
mobil
phase
flow
rate
mlmin
solvent
system
water
trifluoroacet
acid
water
vvv
vvv
linear
gradient
min
reequilibr
min
initi
condit
triplic
inject
l
made
data
quantit
measur
peak
area
correspond
myr
p
allergen
peptid
extract
nm
condit
myr
p
elut
min
myr
p
min
myr
p
min
fig
data
analys
use
water
masslynx
targetlynx
softwar
mean
peak
area
allergen
peptid
calcul
analysi
remain
concentr
allergen
peptid
calcul
percentag
rel
baselin
sampl
analysi
jjav
diluent
stabil
measur
ph
sampl
ph
measur
use
calibr
ph
meter
hanna
instrument
woonsocket
ri
usa
benzyl
alcohol
concentr
determin
uplcuv
use
instrument
column
describ
mobil
phase
flow
rate
mlmin
solvent
system
isocrat
mixtur
acet
acid
water
acetonitril
vv
quadrupl
inject
l
made
data
quantit
measur
extract
nm
maintain
scale
signal
benzyl
alcohol
elut
min
peak
area
determin
use
water
targetlynx
softwar
benzyl
alcoholfre
advax
ad
concentr
benzyl
alcohol
jjav
diluent
reduc
consist
dilut
effect
particl
size
advax
mgml
presenc
jjav
gml
diluent
solut
determin
dynam
light
scatter
dl
use
zetas
nano
malvern
instrument
ltd
worcestershir
uk
sampl
mix
vortex
form
uniform
suspens
transfer
uvett
plastic
cuvett
eppendorf
ag
sampl
compart
temperatur
adjust
c
measur
taken
measur
perform
triplic
averag
particl
size
zaverag
size
particl
size
distribut
via
polydispers
index
pdi
obtain
sampl
analys
endotoxin
content
use
limulu
amebocyt
lysat
chromogen
assay
lonza
walkersvil
md
usa
previous
describ
antimicrobi
efficaci
benzyl
alcohol
jjav
diluent
evalu
use
unit
state
pharmacopoeia
antimicrobi
effect
test
aet
follow
challeng
organ
use
candida
albican
atcc
escherichia
coli
atcc
staphylococcu
aureu
atcc
bacteri
stock
cultur
grown
hour
trypton
soya
broth
yeast
stock
cultur
grown
hour
sabaroud
dextros
broth
microorgan
harvest
centrifug
wash
resuspend
dilut
normal
salin
obtain
microbi
count
approxim
coloni
form
unit
per
ml
cfuml
microbi
suspens
use
within
min
harvest
challeng
organ
aet
conduct
five
replic
test
sampl
consist
l
jjav
diluent
contain
either
jjav
gml
alon
advax
mgml
inocul
microbi
suspens
vv
yield
final
concentr
cfuml
incub
c
day
aliquot
l
taken
sampl
day
number
cfu
sampl
determin
use
platecount
method
posit
control
sampl
l
normal
salin
inocul
microbi
suspens
vv
yield
final
concentr
cfuml
l
aliquot
taken
control
sampl
baselin
number
cfu
determin
use
platecount
method
neg
control
sampl
growth
media
batch
devoid
manipul
assess
potenti
advax
provid
jjav
antigenspar
femal
balbc
mice
week
old
immun
time
intramuscularli
interv
jjav
g
royal
hobart
hospit
tasmania
australia
alon
formul
advax
mg
vaxin
pti
ltd
adelaid
australia
versu
jjav
g
alon
l
total
inject
volum
blood
sampl
collect
week
last
immun
measur
jjavspecif
igg
respons
elisa
jjavspecif
antibodi
elisa
mous
jjavspecif
igg
antibodi
determin
elisa
previous
describ
minor
modif
briefli
jjav
gml
coat
buffer
ph
mm
me
mm
hepe
pb
absorb
well
plate
block
casein
l
dilut
sera
incub
h
rt
follow
wash
incub
biotinyl
antimous
igg
antibodi
abcam
cambridg
usa
mix
hrpconjug
streptavidin
bd
bioscienc
franklin
lake
nj
usa
h
wash
well
incub
tmb
substrat
kpl
gaithersburg
md
usa
min
reaction
stop
phosphor
acid
optic
densiti
measur
nm
od
nm
use
versamax
plate
reader
analys
use
softmax
pro
softwar
molecular
devic
sunnyval
ca
usa
averag
od
nm
valu
obtain
neg
control
well
subtract
statist
analysi
perform
use
graphpad
prism
curveexpert
basic
statist
analys
includ
descript
statist
ttest
anova
bonferroni
posthoc
test
use
appropri
p
consid
signific
imag
analysi
perform
use
imagej
r
wayn
rasband
nation
institut
health
noninferior
analysi
perform
independ
ttest
log
transform
igg
data
assess
whether
upper
limit
confid
interv
differ
treatment
low
dose
adjuv
jjav
treatment
minu
standard
high
dose
jjav
alon
treatment
predefin
margin
noninferior
tabl
describ
accept
criteria
physicochem
microbiolog
stabil
jja
vit
compon
advax
adjuv
allergen
potenc
jjav
baselin
significantli
affect
presenc
advax
formul
p
supplementari
tabl
overal
allergen
potenc
jjav
without
advax
accept
least
day
store
c
rel
allergen
potenc
stabil
sampl
effect
advax
mgml
storag
temperatur
c
c
allergen
potenc
jjav
gml
store
day
analysi
allergen
potenc
calcul
percentag
rel
baselin
sampl
sampl
analys
triplic
present
mean
sd
asterisk
design
signific
differ
p
p
p
store
c
without
advax
respect
stabil
sampl
store
c
without
advax
respect
fig
trend
progress
increas
allergen
potenc
observ
gml
jjav
stabil
sampl
continu
increas
beyond
accept
limit
day
storag
either
c
particularli
stabil
sampl
advax
fig
myr
p
least
stabl
allergen
quantifi
via
uplcuv
stabil
limit
stabil
myr
p
fig
therefor
presenc
advax
jjav
stabl
day
store
c
c
respect
fig
signific
differ
found
without
advax
either
baselin
sampl
supplementari
tabl
one
stabil
pair
fig
sdspage
result
show
protein
band
approxim
kda
disappear
slowli
throughout
storag
period
appear
replac
new
band
approxim
kda
fig
chang
occur
regardless
sampl
treatment
obviou
prolong
storag
similar
pattern
also
observ
sdspage
immunoblot
result
wherebi
igebind
band
kda
slowli
disappear
replac
new
igebind
band
kda
fig
chang
occur
regardless
advax
obviou
stabil
sampl
store
c
h
effect
advax
mgml
storag
temperatur
c
c
allergen
potenc
jjav
gml
b
gml
c
gml
store
day
analysi
calcul
percentag
rel
baselin
sampl
sampl
analys
triplic
present
mean
sd
addit
advax
caus
substanti
chang
ph
jjav
diluent
fig
storag
temperatur
minim
effect
stabil
benzyl
alcohol
period
studi
fig
advax
delta
inulin
microparticl
mean
hydrodynam
diamet
baselin
fig
chang
storag
c
day
respect
twofold
increas
diamet
observ
day
studi
endpoint
c
polydispers
index
pdi
advax
approxim
baselin
chang
substanti
day
studi
period
although
notic
fluctuat
time
particularli
sampl
store
c
pdi
increas
day
studi
period
c
fig
batch
jja
vit
jjav
diluent
advax
virtual
free
endotoxin
supplementari
tabl
steril
test
jja
vit
jjav
diluent
support
asept
natur
combin
formul
data
shown
sampl
includ
jjav
diluent
contain
jjav
sampl
advax
ad
met
pharmacopoei
requir
antimicrobi
activ
sampl
time
point
supplementari
tabl
murin
immunogen
model
use
test
hypothesi
advax
adjuv
could
use
jjav
dose
spare
confirm
neg
effect
safeti
toler
femal
balbc
mice
week
age
n
immun
time
intramuscularli
interv
jjav
g
alon
combin
mg
advax
adjuv
versu
jjav
g
fig
particl
size
distribut
advax
mgml
function
zaverag
b
polydispers
index
pdi
combin
jjav
gml
store
day
either
c
c
analysi
perform
use
diffract
light
scatter
techniqu
sampl
analys
triplic
present
mean
sd
alon
aim
assess
noninferior
jjav
specif
igg
respons
jjav
g
advax
low
dose
group
compar
jjav
g
high
dose
group
blood
sampl
collect
week
last
immun
measur
jjavspecif
total
igg
igg
subtyp
elisa
low
undetect
level
jjavspecif
igg
seen
anim
immunis
g
jjav
alon
anim
low
dose
jjav
g
advax
arm
detect
jjavspecif
igg
formal
noninferior
analysi
perform
use
prespecifi
limit
confirm
low
dose
jjav
advax
arm
statist
noninferior
high
dose
jjav
alon
group
p
subsequ
test
superior
confirm
jjavspecif
igg
respons
low
dose
jjav
advax
arm
superior
p
high
dose
alon
arm
fig
henc
advax
confirm
provid
least
jjav
dosespar
analysi
igg
isotyp
confirm
predomin
effect
advax
adjuv
predominantli
signific
enhanc
specif
rather
jjavspecif
ige
detect
sera
immun
mice
local
swell
red
hair
loss
system
weight
loss
fever
inact
loss
groom
advers
effect
observ
preclin
studi
novel
adjuv
allergenspecif
immunotherapi
ait
formul
gener
requir
regulatori
author
prior
initi
clinic
trial
studi
demonstr
physicochem
microbiolog
compat
adjuv
antigen
compon
contain
within
vaccin
togeth
immunogen
data
justifi
inclus
adjuv
vaccin
although
mani
human
trial
conduct
advax
adjuv
combin
variou
infecti
diseas
vaccin
one
studi
advax
honeybe
vit
inform
previous
avail
formul
stabil
immunogen
jjav
antigen
presenc
advax
current
studi
perform
stabil
studi
lowdos
jja
vit
without
advax
adjuv
prepackag
plastic
syring
therebi
confirm
jja
vit
advax
compon
compat
minim
aggreg
delta
inulin
microparticl
observ
period
studi
base
data
obtain
particular
allergen
potenc
studi
lowdos
jja
vit
formul
advax
physicochem
microbiolog
stabl
least
day
store
c
c
plastic
syring
allow
lowdos
jja
vit
formul
without
advax
prepar
central
pharmaci
locat
advanc
clinic
trial
use
transport
site
patient
administr
remov
need
prepar
vaccin
patient
bedsid
may
reduc
likelihood
error
dose
occur
jjav
stabil
result
obtain
current
studi
consist
previou
report
although
condit
employ
somewhat
differ
particular
current
studi
use
plastic
insulin
syring
store
sampl
lower
concentr
jjav
use
previou
studi
measur
total
allergen
activ
determin
elisa
inhibit
assay
requir
regulatori
bodi
standard
izat
batch
control
ait
product
slight
increas
jjav
allergen
activ
storag
entir
consist
previou
find
propos
due
conform
chang
jjav
protein
presenc
polysorb
jjav
diluent
despit
elisa
inhibit
data
indic
vast
major
allergen
activ
preserv
exclud
possibl
one
minor
allergen
might
degrad
perhap
better
monitor
use
immunoblot
assay
observ
shift
kda
band
recent
found
phospholipas
enzym
band
approxim
kda
fig
pattern
allergen
degrad
consist
prior
find
affect
inclus
advax
formul
wanandi
et
al
recent
report
adsorpt
myr
p
myr
p
allergen
jjav
api
grade
product
allow
contact
rubber
stopper
h
even
though
lowdos
jjav
current
studi
store
plastic
syring
rubber
plunger
neglig
adsorpt
identifi
differ
might
due
inclus
polysorb
surfac
activ
agent
current
sampl
differ
adsorpt
capac
surfac
area
rubber
jjav
solut
gml
use
immunotherapi
intend
multidos
use
addit
benzyl
alcohol
antimicrobi
preserv
jjav
diluent
essenti
reduc
risk
bacteri
contamin
insignific
chang
ph
jjav
diluent
presenc
advax
import
solubl
optim
antimicrobi
activ
benzyl
alcohol
consider
reduc
ph
use
antimicrobi
preserv
benzyl
alcohol
commonli
ad
parenter
prepar
concentr
reduct
benzyl
alcohol
concentr
jjav
diluent
due
dilut
effect
addit
advax
reduc
concentr
benzyl
alcohol
usual
rang
could
therefor
affect
effect
preserv
howev
aet
experi
confirm
antimicrobi
efficaci
combin
formul
challeng
organ
maintain
throughout
studi
period
possibl
due
least
part
inher
antimicrobi
activ
jjav
provid
addit
synergist
effect
preserv
activ
benzyl
alcohol
case
sinc
low
concentr
venom
protein
use
induct
phase
vit
greater
relianc
antimicrobi
efficaci
benzyl
alcohol
requir
phase
pdi
suggest
monodispers
prepar
result
studi
show
advax
rel
monodispers
particl
size
distribut
start
studi
indic
pdi
increas
averag
particl
size
pdi
observ
end
studi
period
may
caus
format
delta
inulin
aggreg
howev
absenc
multimod
peak
sampl
test
throughout
studi
period
suggest
aggreg
present
limit
studi
condit
employ
importantli
size
particl
within
accept
rang
stabil
tabl
advax
report
minim
protein
adsorpt
capac
similarli
found
evid
advax
adsorb
jjav
allergen
minim
differ
sdspage
uplcuv
analysi
venom
compon
sampl
formul
without
advax
notabl
murin
immunogen
data
support
hypothesi
advax
adjuv
provid
signific
antigenspar
jja
vit
induc
significantli
higher
serum
jjavspecif
igg
level
mice
receiv
adjuv
venom
formul
five
time
higher
dose
jjav
alon
whilst
current
anim
model
jjav
allergi
henc
effect
advax
inhibit
jjav
ige
vit
abil
induc
block
antibodi
unabl
assess
outsid
human
studi
abil
advax
enhanc
venomspecif
igg
respons
compar
immunis
venom
alon
serv
use
predict
marker
favour
human
respons
previou
human
studi
advaxadjuv
honeybe
vit
inclus
advax
led
earlier
higher
rise
venomspecif
total
igg
potenti
block
activ
henc
current
result
support
rational
plan
human
trial
advax
combin
reduc
dose
jjav
g
mainten
phase
compar
current
clinic
proven
g
mainten
jjav
dose
notabl
safeti
reactogen
issu
identifi
advaxadjuv
low
dose
jjav
formul
current
studi
advax
adjuv
provid
least
jjav
antigen
spare
murin
immunogen
studi
observ
issu
reactogen
safeti
detriment
effect
advax
jjav
stabil
found
support
use
combin
formul
jjavspar
strategi
plan
human
trial
plan
place
commenc
human
clinic
trial
assess
abil
advax
reduc
requir
mainten
dose
jjav
g
per
dose
success
would
result
higher
number
subject
abl
treat
jja
vit
current
suppli
also
significantli
reduc
potenti
cost
therapi
larg
reflect
jjav
cost
